What is your typical exit strategy?

We focus on building fully-fledged standalone companies capable of reaching >USD 100m in annual revenues. However, as is common in healthcare, private specialised companies are often acquired by global strategics through a trade sale which provides an exit opportunity. A company may also be a good target for a public offering allowing us to exit or cross-over our investments into public markets. Three of our portfolio companies became publicly traded companies in 2021. Reviewing potential exit scenarios is a key part of our due diligence before investing in a company.